Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine develops investigational treatments for serious hematologic diseases by targeting red blood cell biology, including heme biosynthesis and iron homeostasis. News about IRON centers on its clinical-stage pipeline, including bitopertin for erythropoietic protoporphyria, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders.
Recurring updates include clinical trial progress, medical-meeting presentations, FDA communications, quarterly financial results, business updates, investor-conference participation, and leadership or organizational changes tied to the company’s development and commercialization planning.
Disc Medicine (NASDAQ: IRON) reported updated clinical data at the 2026 EHA meeting. Phase 2 RALLY-MF results for DISC-0974 in myelofibrosis anemia showed meaningful, durable anemia responses across transfusion subgroups and with/without JAK inhibitors, with generally favorable tolerability. Phase 2 HELIOS extension data for bitopertin in EPP showed sustained PPIX reductions, improved light tolerance, and longer-term safety. The company plans End-of-Phase 2 FDA discussions for DISC-0974 in 2026, a Phase 3 APOLLO readout for bitopertin in Q4 2026, and initial Phase 2 RESTORE-PV data for DISC-3405 in Q4 2026, and will host a corporate update call on June 15.
Disc Medicine (NASDAQ:IRON) completed a Type A FDA meeting on the Complete Response Letter for bitopertin in erythropoietic protoporphyria (EPP).
The FDA agreed that the ongoing Phase 3 APOLLO study, if successful, can support the CRL response and potentially a traditional approval. APOLLO data are expected in Q4 2026, with a CRL response planned by end-2026 and an FDA decision anticipated by mid-2027.
Disc Medicine (NASDAQ:IRON) reported updated RALLY-MF Phase 2 data for DISC-0974 in myelofibrosis-related anemia at ASCO 2026.
According to the company, treatment reduced hepcidin by >75%, increased serum iron, produced durable hemoglobin and transfusion responses across subgroups, improved fatigue scores, and was generally well tolerated, supporting an FDA end-of-Phase 2 meeting in 2026.
Disc Medicine (NASDAQ:IRON) launched an expanded access program (EAP) in the U.S. for investigational drug bitopertin for eligible erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) patients.
Bitopertin, an oral GlyT1 inhibitor, is in the double-blind, placebo-controlled Phase 3 APOLLO trial in patients 12+ years, with topline data expected in Q4 2026 and a potential FDA decision by mid-2027.
Disc Medicine (NASDAQ: IRON) will present multiple hematology program updates at the EHA 2026 Congress in Stockholm on June 11-14, 2026.
Highlights include Phase 2 RALLY-MF data for DISC-0974 in myelofibrosis anemia, new bitopertin EPP data, a European EPP LIGHT survey, and a DISC-3405 Phase 2 PV trial-in-progress poster, plus a June 15 corporate update call.
Disc Medicine (NASDAQ:IRON) announced participation in two upcoming investor conferences. Management will host fireside chats at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 19 at 4:30 p.m. ET and the Jefferies Global Healthcare Conference on June 3 at 3:10 p.m. ET.
Live webcasts and archived replays will be available on the company’s investor relations website.
Disc Medicine (NASDAQ:IRON) completed enrollment in its Phase 3 APOLLO trial of bitopertin in EPP (expanded to 183 patients) and expects topline APOLLO data in Q4 2026. The company will present updated Phase 2 DISC-0974 data at ASCO and anticipates multiple Q4 2026 readouts. Cash, cash equivalents, and marketable securities were $730.2 million as of March 31, 2026, funding operations into 2029.
Disc Medicine (NASDAQ:IRON) will present Phase 2 RALLY-MF data for investigational DISC-0974 in anemia of myelofibrosis at ASCO 2026 in Chicago, with oral presentation on June 2, 2026.
The abstract (No. 6501) posts online on May 21, 2026; additional, previously unpresented data will be disclosed at the conference. DISC-0974 remains investigational and is not approved for use.
Disc Medicine (NASDAQ:IRON) announced completion of enrollment in the pivotal Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP).
The study was expanded from 150 to 183 participants due to demand, enrolled in less than one year, includes sites in the US, Canada, Europe, and Australia, and plans to report results in Q4 2026 with an FDA decision expected by mid-2027.
Disc Medicine (NASDAQ:IRON) reported Q4 and full-year 2025 results and a program update on Feb 26, 2026. Key points: $791.2M cash runway into 2029, Phase 3 APOLLO for bitopertin enrolling through March 2026 with topline data expected Q4 2026, FDA issued a CRL in Feb 2026. Positive Phase 2 data presented for DISC-0974 in MF anemia; DISC-3405 studies progressing with data due 2H 2026.
Full-year 2025: R&D $170.6M, SG&A $65.4M, net loss $212.2M; cash increased from $489.9M at 2024 year-end largely from $454.4M equity offerings.